Expression, Purification and Characterization of Functional Teduglutide Using GST Fusion System in Prokaryotic Cells [PDF]
Advanced Pharmaceutical Bulletin, 2023 Purpose: Teduglutide is the first and only FDA-approved drug for long-term treatment of short bowel syndrome (SBS). The current study aimed to present an approach for production of teduglutide using recombinant DNA technology.
Ali Akbar Alizadeh +4 more
doaj +2 more sources
Use of Teduglutide in Children With Intestinal Failure: A Systematic Review [PDF]
Frontiers in Nutrition, 2022 Background and ObjectivesShort-bowel syndrome (SBS) results from the loss of a significant portion of the small intestine leading to a state of malabsorption.
Francesca Gigola +8 more
doaj +2 more sources
[Is there life after teduglutide?]
Nutricion hospitalaria, 2021 Intestinal failure (IF) is defined as a reduction in intestinal function below the minimum necessary for the absorption of nutrients, requiring intravenous supplementation to maintain health and/or growth. The most common cause is short bowel syndrome (SBS). Approximately 50% of patients with SBS have IF and require parenteral support. Teduglutide is a
Adela Leyre, Martínez Martínez +9 more
openaire +3 more sources
Review of real-life teduglutide experience [PDF]
Nutrición Hospitalaria, 2023 Background: teduglutide is an agonist of glucagon-related peptide (aGLP2) effective as a treatment for patients with short bowel syndrome (SBS), an entity that affects quality of life, usually requires home parenteral nutrition (HPN) and generates significant health costs.
Irles Rocamora, José A. +3 more
openaire +4 more sources
Effect of teduglutide, a glucagon-like peptide-2 analog, in eosinophilic enterocolitis: a case report [PDF]
Frontiers in PediatricsWe successfully treated a 4-year-old girl with short bowel syndrome and eosinophilic enterocolitis with teduglutide, a glucagon-like peptide-2 analog.
Shoko Ogawa +7 more
doaj +2 more sources
Efficacy of Teduglutide in Pediatric Short Bowel Syndrome: Association with Citrulline Levels and Anatomical Location of Remnant Small Intestine [PDF]
ChildrenBackground/Objectives: Short bowel syndrome (SBS) is the leading cause of pediatric intestinal failure. Plasma citrulline is considered a marker indicating an enterocyte volume and may help evaluate the response to teduglutide; however, this ...
Yudai Goto +6 more
doaj +2 more sources
Bridging intestinal failure with Teduglutide – A case report
International Journal of Surgery Case Reports, 2021 Abstract Introduction and importance Intestinal failure (IF) describes the state of a person's gastrointestinal absorption capabilities becoming unable to absorb fluids and nutrients needed to sustain normal physiology, leading to severe comorbidities and if left untreated, to death. IF is most
Schlager, Lukas +4 more
openaire +3 more sources
Weaning infants with short bowel syndrome associated intestinal failure from parenteral nutrition: An ERNICA multicentre survey [PDF]
Intestinal FailureBackground: To explore and compare practices of European Intestinal Rehabilitation Centres participating in the European Reference Network for rare Inherited and Congenital Anomalies (ERNICA) intestinal failure (IF) working group when weaning short bowel
Susan Hill +7 more
doaj +2 more sources
Glucagon-like peptide-2 pharmacotherapy activates hepatic Farnesoid X receptor-signaling to attenuate resection-associated bile acid loss in mice [PDF]
Molecular MetabolismObjective: Villus growth in the small bowel by Glucagon-like peptide-2 (GLP-2) pharmacotherapy improves intestinal absorption capacity and is now used clinically for the treatment of short bowel syndrome and intestinal failure occurring after extensive ...
Johannes Reiner +15 more
doaj +2 more sources
Teduglutide-induced stem cell function in intestinal repair
Journal of Investigative Surgery, 2018 Malabsorption is a major and common clinical characteristics of short bowel syndrome (SBS) and inflammatory bowel diseases (IBD). Traditional treatment opportunities have focused on decreasing malabsorptive losses via dietary modifications and ...
Ferenc Sipos, Györgyi Műzes
doaj +2 more sources